• james-barder.jpg

    James Barder

    Chief Executive


    Current roles

    James Barder is the Group’s Chief Executive. He assists the Remuneration Committee and the Nominations Committee (but is not a member of and does not vote on either). He has overall responsibility for all activities of the Group, is a principal contact for shareholder and investor relations and leads commercial negotiations. He is also a Non-Executive Director of Caisson IO Group Limited and a Director of the Mary How Trust for Cancer Prevention.

    Past roles

    Managing Director of Aon Capital Markets Limited and Non-Executive Director of Lorega Limited. James predominantly worked in the field of reinsurance and finance including firms he founded.

    Brings to the Board

    Over 30 years of experience in setting up, managing and running companies.

  • james-barder.jpg

    Ken James

    Executive Director and Head of R&D


    Current roles

    Ken James is the Head of R&D. He oversees the development, regulatory and manufacturing strategies for the Group’s existing pipeline and the evaluation of early stage pipeline opportunities. He is also an Executive Director.

    Past roles

    Senior Vice President of Research and Development for GlaxoSmithKline Worldwide Consumer Healthcare, having worked in the UK and the United States.

    Brings to the Board

    Over 40 years’ experience in the research, development and commercialisation of consumer healthcare products.

  • james-barder.jpg

    Angela Hildreth

    Finance Director, Chief Operating Officer and Company Secretary


    Current roles

    Angela joined the Group in 2018. She leads the Group’s finance, HR and IT functions, inputs into commercial and financial strategy, ensures its compliance procedures and is a principal contact for shareholder and investor relations matters. She is also an Independent Non-Executive Director and Chair of the Audit Committee at AIM-listed Aptamer plc.

    Past roles

    Senior financial roles in a diverse range of industries, including seven years as UK Finance Director at Shield Therapeutics plc (quoted on AIM).

    Brings to the Board

    Over 15 years’ strategic and operational financial experience of developing and commercialising pharmaceutical products.

  • james-barder.jpg

    Jeff Needham

    Non-Executive Chairman


    Current roles

    Jeff Needham is Chairman of Futura Medical plc and is a member of the Remuneration Committee. He is also a member of the Nominations Committee. Jeff is currently on the Board of McKee Foods Corp.

    Past roles

    President of Perrigo Consumer Self-Care Americas (including USA) and Executive Vice President at Perrigo Company plc, the US-based manufacturer and marketer of consumer healthcare products, and a board director of the US Consumer Healthcare Products Association for 11 years.

    Brings to the board

    Over 35 years of experience in manufacturing and marketing of consumer healthcare products with strategic and corporate management expertise, with particular expertise in the US market.

  • james-barder.jpg

    Andrew Unitt

    Senior Independent Non-Executive Director


    Current Roles

    Andrew Unitt is an Independent Non-Executive Director and is Chair of the Audit Committee, Nominations Committee and Remuneration Committee.

    Past Roles

    Chief Financial Officer at the University of Nottingham until 2016. Andrew spent eleven years at Boots plc, where he was Managing Director and Finance Director for four years of Boots Healthcare International, its over the counter medicines business. Andrew was also an Independent Non-Executive Director of AIM-listed company Oncimmune Holdings plc.

    Brings to the Board

    Over 20 years of experience as a Finance Director in a wide range of industries with strong financial experience and OTC market expertise.

  • james-barder.jpg

    Roy Davis

    Position


    Roy brings a wealth of commercial experience in medical devices companies and has a proven track record of successfully scaling companies and delivering substantial value for shareholders. He has held leadership positions at a number of publicly quoted med tech companies, including CEO of Optos plc, a leading retinal imaging device manufacturer, from 2008 to 2016 until its sale to Nikon for £259m in February 2015. From 2007 to 2008, Roy was CEO of Gyrus Group plc, a leader in minimally invasive surgery and visualisation, until its acquisition by Olympus Corporation in 2008 for $1.9 billion.

    He is currently Non-Executive Chair at LungLife AI plc, Foster and Freeman (the trading name of the Galton group of companies) and Rair Health Ltd and was until recently, Non-Executive Chair at Medica Group plc until its acquisition by IK Partners for £269 million earlier this year.  On 7 December it was announced that Roy will become a Non-Executive Director and Chair Designate of Inspiration Healthcare Group plc with effect from 25 January 2024.